Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
28 Diffuse Pontine Glioma Trials Near You
Power is an online platform that helps thousands of Diffuse Pontine Glioma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerSurVaxM Vaccine for Brain Cancer
Columbus, Ohio
This trial tests the SurVaxM vaccine, which helps the immune system target and destroy cancer cells, in children and young adults with certain difficult-to-treat brain cancers. The vaccine works by teaching the immune system to recognize a protein found in cancer cells. Additional substances are used to make the immune response stronger.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:1 - 21
Key Eligibility Criteria
Disqualifiers:Active Infection, Autoimmune Disease, Others
Must Not Be Taking:Cannabidiol, Medical Marijuana, Others
35 Participants Needed
PEP-CMV Vaccine for Pediatric Brain Tumor
Columbus, Ohio
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB).
PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51.
Funding Source - FDA OOPD
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:3 - 39
Key Eligibility Criteria
Disqualifiers:Pregnancy, HIV, Active Infection, Others
Must Not Be Taking:Immunosuppressants, Tumor-directed Therapy
120 Participants Needed
Combination Therapy for Brain Cancer
Columbus, Ohio
This trial is testing a combination of three drugs to treat a specific type of brain tumor called diffuse midline gliomas (DMGs). These drugs aim to stop the tumor from growing by blocking enzymes that the cancer cells need. The trial focuses on patients with DMGs because current treatments are not very effective for them.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:2 - 39
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Others
Must Not Be Taking:CYP3A4/5 Inhibitors, Inducers
360 Participants Needed
Fimepinostat for Brain Cancer
Columbus, Ohio
This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:3 - 39
Key Eligibility Criteria
Disqualifiers:Diabetes, HIV, Cardiac Arrhythmia, Others
Must Not Be Taking:HDAC Inhibitors, PI3K Inhibitors
30 Participants Needed
PTC596 + Radiotherapy for Brain Tumor
Columbus, Ohio
The goal of this study is to evaluate the safety of the study drug PTC596 (Unesbulin) taken in combination with radiotherapy (RT) when given to pediatric patients newly diagnosed with High-Grade Glioma (HGG) including diffuse intrinsic pontine glioma (DIPG).
The main aims of the study are to:
* Find the safe dose of the study drug PTC596that can be given without causing serious side effects.
* Find out the amount of drug that enters blood (in all patients) and tumor (in patients who receive drug prior to a planned surgery for removal of their brain tumor)
During the first cycle (6-7weeks), patients will receive drug orally twice a week in combination with daily RT. During subsequent cycles (4 weeks each), they will receive only the study drug orally twice a week.
Funding Source - FDA OOPD
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:12 - 21
Key Eligibility Criteria
Disqualifiers:Pregnancy, Oligodendroglioma, Uncontrolled Infection, Others
Must Not Be Taking:Investigational Drugs, Anticancer Agents
64 Participants Needed
Ribociclib + Everolimus for Brain Tumors
Columbus, Ohio
This trial is testing whether the combination of ribociclib and everolimus can help children and young adults with aggressive brain tumors live longer. Everolimus is a medication that has been approved for treating various cancers. These drugs are taken by mouth and work by stopping cancer cells from growing. The study focuses on patients whose tumors have specific genetic changes that make them hard to treat with standard therapies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 39
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Infection, Others
Must Not Be Taking:Investigational Drugs, Anticancer Agents, Others
100 Participants Needed
ACT001 for Brain Cancer
Columbus, Ohio
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:12 - 39
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Uncontrolled Infection, Transplant, Pregnancy, Others
Must Not Be Taking:Anticancer Agents, Investigational Drugs
60 Participants Needed
Savolitinib for Brain Tumors
Columbus, Ohio
This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:6 - 21
Key Eligibility Criteria
Disqualifiers:Pregnancy, Serious Infection, Uncontrolled Hypertension, Cardiac Diseases, Others
Must Not Be Taking:CYP3A4 Inducers, CYP3A4 Inhibitors
41 Participants Needed
Selinexor + Radiation for Brain Cancer
Columbus, Ohio
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:12 - 21
Key Eligibility Criteria
Disqualifiers:Not Listed
210 Participants Needed
Palbociclib + Chemotherapy for Solid Tumors
Columbus, Ohio
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn about the efficacy of palbociclib in combination with irinotecan and temozolomide when compared with irinotecan and temozolomide alone in the treatment of children, adolescents, and young adults with recurrent or refractory Ewing sarcoma (EWS).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 20
Key Eligibility Criteria
Disqualifiers:Brain Tumors, Cardiac Disease, Infections, Others
Must Not Be Taking:Strong CYP3A Inhibitors, Strong UGT1A1 Inhibitors
128 Participants Needed
Lorlatinib for Brain Tumors
Columbus, Ohio
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Early Phase 1
Age:1 - 21
Key Eligibility Criteria
Disqualifiers:Pregnancy, Organ Transplant, Psychiatric Disorder, Others
Must Not Be Taking:Investigational Drugs, Anti-cancer Agents
15 Participants Needed
Olutasidenib + Temozolomide for Brain Tumors
Columbus, Ohio
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 39
Key Eligibility Criteria
Disqualifiers:Pregnancy, HIV, Metastatic HGG, Others
Must Be Taking:Temozolomide
60 Participants Needed
Abemaciclib Combination Therapy for Neuroblastoma
Columbus, Ohio
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:< 21
Key Eligibility Criteria
Disqualifiers:Not Listed
117 Participants Needed
Larotrectinib for Brain Cancer
Columbus, Ohio
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given.
The study will also evaluate the safety of larotrectinib when given with chemotherapy in your children; as well as the safety larotrectinib when given post-focal radiation therapy.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:< 21
Key Eligibility Criteria
Disqualifiers:Pregnancy, Infection, Organ Transplant, Others
Must Not Be Taking:Investigational Drugs, Anti-cancer Agents, CYP3A4 Inhibitors
15 Participants Needed
Lutathera for Brain Tumor
Columbus, Ohio
This trial tests Lutathera, a radioactive drug given through an IV, in patients with certain brain tumors that haven't responded to other treatments. The drug attaches to cancer cells and uses radiation to kill them.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:4+
Key Eligibility Criteria
Disqualifiers:Bone Marrow Metastasis, Bulky Disease, Breast-feeding, Type I Diabetes, Others
Must Not Be Taking:Anti-cancer Drugs
65 Participants Needed
INCB7839 for Brain Cancer in Children
Cincinnati, Ohio
This trial tests INCB7839, a drug that blocks proteins helping cancer cells grow, on children with tough-to-treat brain tumors that have returned or grown after initial treatment. The drug works by stopping a protein needed for tumor growth from being released.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:3 - 21
Key Eligibility Criteria
Disqualifiers:Not Listed
13 Participants Needed
CBL0137 for Cancer
Cincinnati, Ohio
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 30
Key Eligibility Criteria
Disqualifiers:Pregnancy, Peripheral Vascular Disease, Others
Must Not Be Taking:Corticosteroids, Anti-cancer Agents, CYP3A4 Drugs, Others
95 Participants Needed
Optune System for Pediatric Brain Cancer
Cincinnati, Ohio
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the feasibility and efficacy of concurrent Optune and standard focal radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum 2).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:3 - 21
Key Eligibility Criteria
Disqualifiers:Other Malignancy, Cardiac Disorder, Others
Must Not Be Taking:Anticancer Drugs, Investigational Drugs
80 Participants Needed
Indoximod + Chemotherapy/Radiation for Pediatric Brain Cancer
Cincinnati, Ohio
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism has been implicated in regulating immune responses in settings as diverse as infection, tissue/organ transplant, autoimmunity, and cancer. By inhibiting the IDO pathway, we hypothesize that indoximod will improve antitumor immune responses and thereby slow the growth of tumors.
The central clinical hypothesis for the GCC1949 study is that inhibiting the pivotal IDO pathway by adding indoximod immunotherapy during chemotherapy and/or radiation is a potent approach for breaking immune tolerance to pediatric tumors that will improve outcomes, relative to standard therapy alone.
This is an NCI-funded (R01 CA229646, MPI: Johnson and Munn) open-label phase 2 trial using indoximod-based combination chemo-radio-immunotherapy for treatment of patients age 3 to 21 years who have progressive brain cancer (glioblastoma, medulloblastoma, or ependymoma), or newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Statistical analysis will stratify patients based on whether their treatment plan includes up-front radiation (or proton) therapy in combination with indoximod. Central review of tissue diagnosis from prior surgery is required, except non-biopsied DIPG. This study will use the "immune-adapted Response Assessment for Neuro-Oncology" (iRANO) criteria for measurement of outcomes. Planned enrollment is up to 140 patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:3 - 21
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Infection, Autoimmune Disease, Others
140 Participants Needed
Pembrolizumab for Pediatric Brain Cancer
Cincinnati, Ohio
This trial studies the safety and effectiveness of pembrolizumab in younger patients with aggressive or treatment-resistant brain tumors. Pembrolizumab is an immunotherapy drug that helps the immune system attack cancer by blocking a protein that stops immune cells from working effectively. Pembrolizumab has been used in various cancers, showing effective antitumor activity and is approved by the FDA for multiple uses.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:1 - 30
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Pneumonitis, Other Malignancies, Others
Must Not Be Taking:Systemic Steroids, Immunosuppressive Agents
110 Participants Needed
Why Other Patients Applied
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
CLR 131 for Pediatric Cancer
Cincinnati, Ohio
This trial is testing CLR 131, a radioactive medicine designed to target and kill cancer cells. It is aimed at children, adolescents, and young adults whose cancers have returned or do not respond to other treatments. CLR 131 works by delivering radiation directly to the cancer cells, reducing harm to healthy cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:2 - 25
Key Eligibility Criteria
Disqualifiers:CNS Metastases, I-131 Dose > 54 MCi/kg, Others
Must Not Be Taking:Antitumor, Investigational
30 Participants Needed
Cobolimab + Dostarlimab for Cancer
Cincinnati, Ohio
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:0 - 21
Key Eligibility Criteria
Disqualifiers:Uncontrolled CNS Involvement, Cardiovascular Disease, Respiratory Disease, Others
Must Not Be Taking:Immunosuppressants, Systemic Steroids
95 Participants Needed
APX005M for Pediatric Brain Cancer
Cincinnati, Ohio
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed diffuse intrinsic pontine glioma. APX005M can trigger activation of B cells, monocytes, and dendritic cells and stimulate cytokine release from lymphocytes and monocytes. APX005M can mediate a direct cytotoxic effect on CD40+ tumor cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:1 - 21
Key Eligibility Criteria
Disqualifiers:Systemic Illness, Bulky Tumor, Others
Must Not Be Taking:Corticosteroids, Immunosuppressives
32 Participants Needed
rHSC-DIPGVax + Checkpoint Inhibitors for Brain Tumor
Chicago, Illinois
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:12 - 18
Key Eligibility Criteria
Disqualifiers:Disseminated Disease, Autoimmune, Respiratory, Others
Must Not Be Taking:Temozolomide
36 Participants Needed
Focused Ultrasound + Chemotherapy for Pediatric Brain Tumor
Washington, District of Columbia
This trial is testing a new way to treat children with a difficult-to-treat brain tumor called DIPG. It uses a device to temporarily open the brain's protective barrier so that a cancer drug, Doxorubicin, can enter and target the tumor. The goal is to see if this method is safe and effective. Doxorubicin is a well-known chemotherapy drug, but its effectiveness in treating brain tumors like DIPG has been limited due to the blood-brain barrier.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:5 - 21
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Hypertension, Epilepsy, Others
Must Not Be Taking:Bevacizumab, Anticoagulants, NSAIDs, Statins
10 Participants Needed
Adoptive Cellular Therapy for Brain Cancer
Hershey, Pennsylvania
A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) and Autologous G-CSF mobilized Hematopoietic Stem Cells (HSCs)).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:1 - 30
Key Eligibility Criteria
Disqualifiers:Autoimmune, Immunosuppressive, Organ Dysfunction, Others
Must Not Be Taking:Investigational Drugs
24 Participants Needed
PEP-CMV + Nivolumab for Brain Cancer
Durham, North Carolina
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Age:4 - 25
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Infection, HIV, Others
Must Not Be Taking:Immunosuppressants, Tumor-directed Therapy
68 Participants Needed
Atovaquone + Radiation for Pediatric Brain Cancer
Atlanta, Georgia
The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/DIPG).
The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGG/DMG/DIPG and medulloblastoma (MB) or pHGG/DMG/DIPG after completion of RT and before progression.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:2 - 25
Key Eligibility Criteria
Disqualifiers:Chronic Illness, Metastatic Tumor, Uncontrolled Seizures, Others
18 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do Diffuse Pontine Glioma clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do Diffuse Pontine Glioma clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Diffuse Pontine Glioma trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Diffuse Pontine Glioma is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a Diffuse Pontine Glioma medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest Diffuse Pontine Glioma clinical trials ?
Most recently, we added ACT001 for Brain Cancer, Lorlatinib for Brain Tumors and PEP-CMV + Nivolumab for Brain Cancer to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.